Phase 2b/3 study of AT-001
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs N-acetylcysteine-amide (Primary)
- Indications Dementia; Familial cerebral amyloid angiopathy
- Focus Therapeutic Use
- 24 Jan 2025 New trial record
- 22 Jan 2025 According to Arctic Therapeutics media release, European Medicines Agency (EMA) approved a pivotal phase IIb/III clinical trial evaluating AT-001 for the treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare form of familial dementia.